Eyas Medical Imaging is highlighting the first installation of its neonatal MRI system Ascent within Cincinatti Children's Hospital's neonatal intensive care unit (NICU).
The system is not yet cleared by the U.S. Food and Drug Administration (FDA) for commercial use in the U.S. The company said it selected the hospital to conduct research studies involving Ascent. Eyas said it hopes to apply for 510(k) clearance in the future.
The Ascent uses a 3-tesla magnet, which translates to improved accuracy in neonatal diagnostic imaging, which in turn could lead to improved patient treatment plans and outcomes for vulnerable infants, according to the firm. The system can also be installed directly within the neonatal unit, eliminating the challenge of transporting fragile newborns.
Eyas said that pending FDA clearance, the Ascent system will provide infants the same access and care standards that adults currently have with MRI exams. Incoming CEO Matt Storer will lead efforts to obtain such clearance. Storer was previously an executive with Procter & Gamble and is an executive in residence for CincyTech, which led seed-stage financing for Eyas.
